  |
|
|
21.05.2012 Capital
increase in Lundbeck as a result of employee warrant
programme and buy-back of shares to fund Long-Term
Incentive scheme |
|
|
|
H.Lundbeck
A/S
(Lundbeck)
today announced that it has
decided to increase its share capital by DKK 2,965, as a
consequence of the exercise of employee warrants. The
increase is affected without any preemption rights for
the existing shareholders of the company or others. The
shares are subscribed in cash at the following prices
per share of nominally DKK 5: 593 shares at DKK 102.
Proceeds to the company are DKK 60,486.00 (approximately
USD 10,400). The increase corresponds to approximately
0.0003% of the company's share capital. |
 |
|
 |
|
|
|
|
|
|
  |
|
|
|
21.05.2012 600 Patients
Recruited in Active Biotech's and Ipsen's tasquinimod
Clinical Phase III Study
|
|
|
|
Active Biotech
(NASDAQ OMX NORDIC: ACTI) and
Ipsen
(Euronext: IPN; ADR: IPSEY)
today announced that
recruitment to the global, pivotal, randomized,
double-blind, placebo-controlled phase III study of
tasquinimod in patients with metastatic
castrate-resistant prostate cancer (CRPC) has reached an
inclusion of 600 patients, half of the planned accrual.
This triggers a €10 million milestone payment from Ipsen
to Active Biotech. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.05.2012 Active Biotech and Ipsen to present
Tasquinimod Phase II Overall Survival data at the
2012 ASCO Annual Meeting
|
|
|
|
Active
Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext:
IPN; ADR: IPSEY)
will present
tasquinimod (TASQ), their prostate cancer drug
candidate, at the scientific conference "2012 ASCO
Annual Meeting" to be held in Chicago (USA) on 1-5 June
2012. The presentation will provide overall survival
(OS) data from the tasquinimod Phase II study in
chemotherapy-naïve metastatic castrate resistant
prostate cancer (CRPC).
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
17.05.2012 MolMed clinical
development update: six abstracts accepted for
presentation at ASCO 2012 |
|
|
|
MolMed S.p.A.
(Milan:MLM) today
announced that six abstracts featuring its
investigational therapeutics NGR-hTNF and TK have been
accepted for presentation at the 48th ASCO Annual
Meeting, that will take place in Chicago (IL, USA) from
June 1-5, 2012. The abstracts are now available on the
ASCO 2012 website (http://chicago2012.asco.org/).
|
 |
|
|
|
|
|
|
|
|
|
  |
|
|
|
16.05.2012
Amgen's BiTE® Antibody Blinatumomab (AMG 103)
Achieved High Rate Of Complete Response In
Adult Patients With Relapsed Or Refractory
Acute Lymphoblastic Leukemia |
|
|
|
Amgen (NASDAQ:AMGN) today announced
updated results from a Phase 2 study
that showed treatment with blinatumomab
(AMG 103) helped achieve a high-rate of
complete response (CR) in 72 percent of
adult patients with relapsed or
refractory B-precursor acute
lymphoblastic leukemia (ALL) treated in
the study. Blinatumomab is the first of
a new class of agents called bi-specific
T cell engagers (BiTE®) antibodies,
designed to harness the body's
cell-destroying T cells... |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.05.2012 ACADIA
Pharmaceuticals to Webcast Educational Program on
Parkinson’s Disease Psychosis on May 22, 2012 |
|
|
|
ACADIA
Pharmaceuticals Inc. (NASDAQ:
ACAD), a biopharmaceutical company focused
on innovative treatments that address unmet medical
needs in neurological and related central nervous system
disorders, today announced that it will host a live
webcast of its Educational Program on Parkinson’s
Disease Psychosis to be held with analysts and investors
in New York City on Tuesday, May 22, 2012, from 12:00
p.m. to 1:15 p.m. Eastern Time. |
 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
15.05.2012 MOLOGEN AG:
Promising start to 2012 business year - Quarterly report
submitted |
|
|
|
The Berlin biotechnology company
MOLOGEN AG
was able to present very good clinical data from the
phase I/II study with product candidate MGN1601 in the
area of renal cancer during the first quarter of 2012. |
 |
|
|
|
|
|
|
|
|
|
  |
|
|
|
15.05.2012 OvPlex ™
distribution expands into India |
|
|
|
HealthLinx Limited (ASX:HTX) with
distribution partners INEX Innovations Exchange Pte Ltd.
and Metropolis Healthcare Ltd. will begin selling
OvPlex™ in India 3rd quarter 2012. OvPlex™
will be available in Mumbai, India from August 1, 2012,
with extension of distribution to take place through all
major Indian cities over the following six months.
|
 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
16.05.2012
Hitting the target: IntelliCap provides reliable and
accurate regional drug delivery |
|
|
|
Medimetrics, recently certified to ISO 13485,
has successfully developed the IntelliCap
system, specifically designed to target delivery
of small molecule drugs and biologics to the GI
tract. The technology is capable of achieving
controlled release of drugs to specific GI sites
in a fast, cost-effective and convenient manner
(Shimizu et al., 2008). This electronic
capsule has the added capability of measuring
quantitative data such as temperature and pH
throughout GI transit. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.2012
Statistically significant clinical phase III results of
Lu AA21004 provide basis for submission of an NDA and
MAA for major depression (MDD) |
|
|
|
H.Lundbeck
A/S
(Lundbeck) today announced positive top-line results
from three recently completed phase III clinical studies
of Lu AA21004, an investigational drug for the treatment
of adults with major depressive disorder (MDD) using
dosages from 10 to 20mg. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.2012 Curetis AG
Achieves CE-Marking for Unyvero™ Solution and Initiates
Commercialization |
|
|
|
Curetis AG, an innovative
molecular diagnostics company focusing on the
development and commercialization of in-vitro diagnostic
products for infectious diseases, today announced that
the company has achieved the CE marking for its Unyvero™
suite of instruments and the P50 Pneumonia Cartridge and
that is has already initiated national and international
commercialization activities. The performance evaluation
of Curetis´ Unyvero™ System and the Unyvero™ P50
Pneumonia cartridge was successfully completed just
recently. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.2012 MOLOGEN AG
- Excellent outcome for phase 2 colorectal cancer study
with MGN1703 - primary endpoint achieved |
|
|
|
The biotechnology company
MOLOGEN AG
has conducted an initial assessment of the phase 2
colorectal cancer study with MGN1703. The assessment of
55 patients showed that the primary endpoint, the
prolongation of the median progression-free survival,
was achieved. Progression-free survival describes the
period in which a cancer disease does not get worse. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.2012
Immuron’s Second Travelan Asia Distribution Agreement |
|
|
|
Australian biopharmaceutical company
Immuron Limited (ASX: IMC), manufacturer of Travelan®,
has entered into an agreement with Singaporean company
Ziwell Medical (S) Pte Ltd for the distribution
of Travelan in Singapore, Malaysia and Brunei.
|
 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
11.05.2012
Oxford BioMedica Interim Management Statement |
|
|
|
Oxford Biomedica
plc (“Oxford
BioMedica” or “the Company”) (LSE: OXB),
the leading gene-based biopharmaceutical
company, today publishes its interim management
statement for the period from 1 January to 10
May 2012. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.05.2012 Vetter Boosts
Quality and Logistic Processes |
|
|
|
The pharma and biotech
industries are increasingly seeking safer and
more efficient supply chain processes. To meet
these challenges
Vetter
has invested in a new, state-of-the-art Center
for Visual Inspection and Logistics. The new
facility offers high-bay warehousing capacity
for cool and room-temperature goods employing
state-of-the-art technology. The contract
development and manufacturing organization
(CDMO) is also setting high safety standards for
quality control at the location. The
35-million-euro facility will serve as a
workplace for up to 400 employees. |
 |
|
|
|
|
|
 |
|
|
|
09.05.2012
Nordion Launches the Gamma Centre of Excellence |
|
|
|
Nordion Inc. (TSX: NDN) (NYSE: NDZ),a leading provider
of products and services for the prevention, diagnosis
and treatment of disease, today launched the Gamma
Centre of Excellence (GCE), a world-class facility for
the advancement of gamma sterilization science. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.05.2012 Immuron
Agreement to Sell Travelan in Thailand, Hong Kong,
Cambodia, Vietnam & Laos |
|
|
|
Australian biopharmaceutical company
Immuron Limited (ASX: IMC), manufacturer of Travelan®,
has entered into an agreement with IntegraMed Asia
(Thailand) Co Ltd for the sale of Travelan in Thailand,
Hong Kong, Cambodia, Vietnam and Laos. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.05.2012 Mucosis Announces
Positive Proof-Of-Concept Data for Mimopath® Platform In
Humans |
|
|
|
Dutch vaccine development company
MUCOSIS B.V.
today announced Phase I clinical data
providing proof-of-concept that Mimopath®-based mucosal
vaccines are safe and well tolerated as well as able to
produce balanced immune responses in both circulating
blood and the respiratory tract. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.05.2012
Definiens Expands Functionality of Its Leading
Solution for Quantitative Digital Pathology with
Gene Probe Analysis |
|
|
|
Definiens®,
the leading provider of image analysis and data
mining solutions for quantitative digital
pathology, today announced that Definiens Tissue
Studio®
3.5 now supports the automated analysis of in
situ hybridization assays, including SISH, CISH,
FISH and dual-ISH. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.05.2012 Cell Therapeutics'
Pixuvri® Approved in European Union as Monotherapy to
Treat Adult Patients with Multiply Relapsed or
Refractory Aggressive Non-Hodgkin B-Cell Lymphomas |
|
|
|
Cell
Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and
MTA: CTIC) today announced that it has received conditional marketing
authorization from theEuropean Commission ("EC")
for Pixuvri® (pixantrone) as
monotherapy for the treatment of adult patients with
multiply relapsed or refractory aggressive non-Hodgkin
B-cell lymphomas ("NHL"). Pixuvri is the first approved
treatment in the European
Union ("EU")
in this patient setting. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.05.2012 Nordion
Launches the Gamma Centre of Excellence |
|
|
|
Nordion Inc. (TSX:
NDN) (NYSE: NDZ),a leading provider of
products and services for the
prevention, diagnosis and treatment of
disease, today launched the Gamma Centre
of Excellence (GCE), a world-class
facility for the advancement of gamma
sterilization science. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.05.2012 Cancer
Support Community Launches National Program to Assist
Patients With Cancer, Make Informed Decisions About Care |
|
|
|
The Cancer Support Community(CSC) and
the Amgen Foundation, today announced
the launch of Open to Options?, a
program designed to bridge the
communications gap between physicians
and patients and inspire patient
confidence in making treatment
decisions. Following a successful pilot
funded by the Centers for Disease
Control (CDC), the Open to Options
program is ready to provide professional
counselors who help more people
formulate a list of personalized
questions and concerns to be taken into
the oncologist's office. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.05.2012
Nuevolution
Announces Receipt of Milestone Payment from Boehringer
Ingelheim |
|
|
|
Nuevolution
A/S today
announced that it has received a milestone payment
derived from its collaboration with Boehringer
Ingelheim. The payment was
triggered following identification of potent small
molecule compounds that have been shown to disrupt the
protein-protein interaction of an undisclosed
therapeutic target. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.05.2012 Lundbeck
announces the resignation of Marie-Laure Pochon,
Executive Vice President, Commercial Operations |
|
|
|
H.Lundbeck
A/S
(Lundbeck) today announced that Marie-Laure Pochon,
Executive Vice President, Commercial Operations, has
decided to resign from her position at Lundbeck for
family and private reasons. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.05.2012
Technologies
Executes Settlement
and License
Agreement with GeneSeek Inc. |
|
|
|
In compliance
with ASX Continuing Disclosure Rules,
Genetic Technologies Limited (ASX: GTG;
NASDAQ: GENE) is pleased to report
that it has executed a Settlement and License Agreement
with GeneSeek Inc. (“GeneSeek”) of Lincoln, Nebraska,
USA (see: http://www.neogen.com/geneseek/).
Under the terms of the Agreement, GeneSeek is
granted certain non-exclusive rights to a number of GTG
patents relating to its non-coding DNA technology.
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.2012 ACADIA
Pharmaceuticals Reports First Quarter 2012 Financial
Results |
|
|
|
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD),
a biopharmaceutical company focused on
innovative treatments that address unmet medical
needs in neurological and related central
nervous system disorders, today announced its
unaudited financial results for the first
quarter ended March 31, 2012. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.2012
Oxford BioMedica Announces Presentation of Ocular
Clinical Data at 2012 ARVO Annual Meeting |
|
|
|
Oxford Biomedica
plc (“Oxford
BioMedica” or “the Company”) (LSE: OXB),
the leading gene-based biopharmaceutical
company, today announces that data from its
ocular programmes partnered with Sanofi
(EURONEXT: SAN and NYSE: SNY) were presented at
the 2012 Annual Meeting of the Association for
Research in Vision and Ophthalmology (ARVO) in
Fort Lauderdale, Florida (USA). |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.05.2012
New data presented at the 2012 Annual Meeting of the
American Psychiatric Association (APA) suggest that
Lu AA21004 may have positive effect on cognitive
dysfunction in patients with major depressive
disorders |
|
|
|
H.Lundbeck
A/S today
announced the presentation of new data on Lu
AA21004, an investigational compound for the
treatment of major depressive disorder
(MDD), at the 165th
Annual Meeting of the American Psychiatric
Association (APA) in Philadelphia, USA. The
presentations included results from clinical
phase III studies as well as non-clinical
data. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.05.2012 esults from
a clinical phase III study of once-monthly aripiprazole
IM depot formulation for the maintenance treatment of
schizophrenia presented at APA |
|
|
|
H.Lundbeck
A/S and
Otsuka Pharmaceutical Co., Ltd. (Otsuka)
today announced results from a clinical
phase III clinical trial evaluating the
efficacy, safety and tolerability of
once-monthly aripiprazole intramuscular (IM)
depot formulation for the maintenance
treatment of adults with schizophrenia.
Trial results were presented in four poster
presentations at the 165th
Annual Meeting of the American Psychiatric
Association (APA) in Philadelphia, USA.
|
|
|
|
|
|
|
|
|
|
|
04.05.2012
European Cystic
Fibrosis Society Diagnostic Network Group evaluated a
new tool for Cystic Fibrosis diagnosis
|
|
|
|
Last
February TECIL participated
in the Meeting of the ECFS DNWG. The European Cystic
Fibrosis Society Diagnostic Network Working Group (ECFS
DNWG)
was set up to evaluate new diagnostic techniques and to
standardize procedures throughout Europe. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.05.2012
BIAL Established as new
Marketing Partner for Medigene's Drug Veregen® in
Spain and Portugal
|
|
|
|
MediGene AG
(Frankfurt, Prime Standard)
(MDG, Frankfurt, Prime Standard)
announces that its drug
Veregen®
will now be marketed by BIAL Industrial
Farmaceutica, S.A., with immediate effect.
This announcement follows an
agreement
between
Medigene, its previous partner Juste S.A.Q.F
and the Portuguese pharmaceutical company
BIAL. Market launch of Veregen®
ointment in Spain remains scheduled to take
place in the second quarter of 2012. |
 |
|
|
|
|
|
|
|
|
|
 |
|
|
|
03.05.2012 Roche Reports
Positive Study of RoACTEMRA Given by Subcutaneous
Injection |
|
|
|
Roche
today
announced that the SUMMACTA study met its primary
endpoint, showing comparable efficacy of the
subcutaneous (SC) formulation of RoACTEMRA (tocilizumab,
known as ACTEMRA outside Europe) 162 mg weekly compared
to 8 mg/kg RoACTEMRA intravenous (IV) formulation every
4 weeks. A similar proportion of rheumatoid arthritis
(RA) patients in each group achieved an ACR20 response
at Week 24, a measure indicating improvement in the
number of tender and swollen joints, pain scale,
patients’ and physicians’ assessment of improvement and
certain laboratory markers. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.05.2012 Sartorius
Stedim Biotech and c-LEcta Sign Sales Agreement
|
|
|
|
Sartorius
Stedim Biotech
(SSB), a leading
international pharma and biotech supplier, and the
biotechnology specialist
c-LEcta,
announce the signing of a worldwide sales and
distribution agreement for c-LEcta’s proprietary
Serratia marcescens nuclease for biopharmaceutical
applications. The German company specializes in the
development of customized enzymes and production strains
for industrial applications. Based on this agreement,
customized endonuclease will now be available under the
product name “Denarase” through all regular Sartorius
Stedim Biotech sales channels. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.05.2012 Jean-Paul
Prieels joins VAXIMMs Board of Directors |
|
|
|
VAXIMM AG, a Swiss-German biotech
spin-off from Merck KGaA focusing on cancer vaccines,
announced today the appointment of Jean-Paul Prieels as
a new member of its Board of Directors. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.05.2012 Genentech Reports
Positive Study of Actemra Given by Subcutaneous
Injection |
|
|
|
Genentech,
a member of the Roche Group (SIX: RO, ROG; OTCQX:
RHHBY), today announced that the SUMMACTA study met its
primary endpoint, showing comparable efficacy
(non-inferiority) of the subcutaneous (SC) formulation
of ACTEMRA (tocilizumab) 162mg weekly compared to 8
mg/kg ACTEMRA intravenous (IV) formulation every four
weeks. A similar proportion of rheumatoid arthritis (RA)
patients in each group achieved an ACR20 response at
Week 24, a measure indicating improvementinthe number of
tender and swollen joints, pain scale, patients’ and
physicians’ assessment of improvement and certain
laboratory markers. |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.05.2012 Nanobiotix
and Thomas Jefferson University Start Research
Collaboration |
|
|
|
Nanobiotix,
a company developing novel cancer nanotherapeutics
and Thomas Jefferson University, one of Philadelphia’s
premier medical and health sciences universities, today
announced that they have entered into a research
collaboration to accelerate the development of
Nanobiotix’ lead compound NBTXR3 in the US.
Under the terms of the collaboration
agreement, Nanobiotix will fund a 2-year preclinical
research program, which will be directed by Bo Lu, MD,
Professor... |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.05.2012 New product
launches on track and revenue continues to show growth,
excluding Lexapro (US) |
|
|
|
Excluding Lexapro®
revenue in the US,
H.Lundbeck
A/S
reports first quarter revenue of DKK 3,442
million, corresponding to an increase of 2%. Including
revenue from Lexapro revenue was DKK 3,778 million.
Operating profit before depreciation and amortisation
(EBITDA) was DKK 1,123 million, corresponding to an
EBITDA margin of 29.7%. Profit from operations (EBIT)
was DKK 882 million, corresponding to an EBIT margin of
23.3%. Profits were affected by the increase in launch
costs related to Lundbeck’s newer products, as well as
the loss of revenue from Lexapro due to generic
competition. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.05.2012 Medigene Obtains
U.S. Patent for EndoTAG®-1 for the Treatment of
Triple-Negative Breast Cancer
|
|
|
|
MediGene AG
(Frankfurt, Prime Standard) has obtained an
additional patent for oncology drug candidate, EndoTAG®-1,
from the United States Patent and Trademark Office.
Patent No. 8,168,216 protects the use of EndoTAG®-1
in combination with taxanes for the treatment of
triple-negative breast cancer (TNBC). This drug
combination was successfully tested in a phase II
clinical trial in patients with TNBC. This newly granted
patent broadens the existing EndoTAG®-1
patent portfolio and has a regular term until April
2029. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.2012 ACADIA
Pharmaceuticals to Announce First Quarter 2012
Financial Results on May 8, 2012 |
|
|
|
ACADIA
Pharmaceuticals Inc. (NASDAQ:
ACAD), a biopharmaceutical company focused on
innovative treatments that address unmet medical
needs in neurological and related central
nervous system disorders, today announced that
it will report its unaudited financial results
for the first quarter ended March 31, 2012 on
Tuesday, May 8, 2012, after the U.S. financial
markets close. ACADIA's management will host a
conference call and webcast on Tuesday, May 8,
2012, at 5:00 p.m. Eastern Time to discuss
ACADIA’s financial results and development
programs. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.2012
Hatchtech
appoints new CEO and completes financing round |
|
|
|
Specialty pharmaceutical company Hatchtech
Pty Ltd has appointed Dr Ross Macdonald as its
Chief Executive Officer. The company has also
secured additional capital, bringing total funds
raised in the current round to AUD7.8 million.
|
 |
|
|
|
|
|
|
|
|
|
All rights reserved